In addition to regulating tumor-related signaling pathways and the tumor microenvironment, m6A RNA modification has been found to intervene in the resistance of tumor cells to drug treatment by modulating various drug efflux protein transporters (such as ABCG2, ABCC9, ABCC10), drug-metabolizing enzymes (such as CYP2C8), and drug targets (such as p53 R273H), among others [91]. This evidence concerns the gene ABCG2 and neoplasm.